{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:16:20Z","timestamp":1763018180911,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP15K10082"],"award-info":[{"award-number":["JP15K10082"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jsbmb.2020.105698","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T09:57:42Z","timestamp":1589191062000},"page":"105698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Heregulin controls ER\u03b1 and HER2 signaling in mammospheres of ER\u03b1-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy"],"prefix":"10.1016","volume":"201","author":[{"given":"Fumiyo","family":"Fukui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2020.105698_bib0005","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11154-007-9033-5","article-title":"Growth factor signaling in endocrine and anti-growth factor resistant breast cancer","volume":"8","author":"Nicholson","year":"2007","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0020","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s10517-013-2160-y","article-title":"Molecular mechanisms of hormone resistance of breast cancer","volume":"155","author":"Scherbakov","year":"2013","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940600010X","article-title":"ErbB receptors and their ligands in the breast","volume":"8","author":"Zahnow","year":"2006","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/path.1335","article-title":"C-erbB-4\/HER4: friend or foe?","volume":"200","author":"Gullick","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0035","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Holbro","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/CMAR.S56802","article-title":"Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer","volume":"6","author":"Arena","year":"2014","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0045","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1158\/0008-5472.CAN-05-1556","article-title":"Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers","volume":"65","author":"Ishikawa","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1349-7006.2006.00188.x","article-title":"Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy","volume":"97","author":"Miyamoto","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0055","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08021","article-title":"Genes that mediate breast cancer metastasis to the brain","volume":"459","author":"Bos","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0060","first-page":"165","article-title":"Heregulin is\u3000sufficient for the promotion of tumorigenicity and metastasis of breast cancer\u3000cells in vivo","volume":"1","author":"Atlas","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0065","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1158\/1078-0432.CCR-13-0358","article-title":"Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy","volume":"20","author":"Phillips","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0070","first-page":"5821","article-title":"Identification of a cancer stem cell in human brain tumor","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature05384","article-title":"Identification and expansion of human colon-cancer-initiating cells","volume":"445","author":"Ricci-Vitiani","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0080","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","article-title":"Identification of pancreatic cancer stem cells","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0085","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155844","article-title":"Contribution of estrone sulfate to cell proliferation in aromatase inhibitor (AI) -Resistant, hormone receptor-positive breast cancer","volume":"11","author":"Higuchi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0095","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1073\/pnas.1113271109","article-title":"ErbB receptor tyrosine kinase\/NF-\u03baB signaling controls mammosphere formation in human breast cancer","volume":"109","author":"Hinohara","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.jsbmb.2020.105698_bib0100","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1158\/1535-7163.MCT-15-0169","article-title":"Seribantumab, an Anti-ERBB3 antibody, delays the onset of resistance and restores sensitivity to letrozole in an estrogen receptor-positive breast Cancer model","volume":"14","author":"Curley","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"March 11","key":"10.1016\/j.jsbmb.2020.105698_bib0105","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/s41388-017-0030-1","article-title":"Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of\u3000CD44 in breast cancer","volume":"37","author":"Morath","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cas.13155","article-title":"Tumor-derived spheroids: relevance to cancer stem cells and clinical applications","volume":"108","author":"Tatsuya","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0115","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.18632\/oncotarget.2846","article-title":"Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines","volume":"6","author":"Momeny","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0125","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1038\/sj.onc.1205555","article-title":"Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells","volume":"21","author":"Neve","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinations of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0135","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/ijc.22423","article-title":"Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells","volume":"120","author":"Liu","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-008-0011-8","article-title":"Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant","volume":"114","author":"Frogne","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10549-013-2570-6","article-title":"HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients","volume":"139","author":"Bae","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0150","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr2603","article-title":"HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer","volume":"12","author":"Da Silva","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0155","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/19420862.2016.1212147","article-title":"Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds","volume":"8","author":"Malm","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0160","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1186\/1471-2407-14-863","article-title":"Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer","volume":"14","author":"Mitsui","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2003.08.027","article-title":"Autocrine activation of ErbB2\/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines","volume":"43","author":"Gollamudi","year":"2004","journal-title":"Lung Cancer."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131400","article-title":"Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1\/2 inhibitors in cultured breast cancer cell lines","volume":"10","author":"Leung","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0175","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.7314\/APJCP.2014.15.24.10659","article-title":"Effects of rapamycin on cell apoptosis in MCF-7 human breast cancer cells","volume":"15","author":"Tengku Din","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0180","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","article-title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Di Leo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0185","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ejca.2015.03.016","article-title":"Fulvestrant with or without selumetinib, a MEK 1\/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomized placebo-controlled double-blind phase II trial, SAKK 21\/08","volume":"51","author":"Zaman","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0190","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1158\/0008-5472.CAN-05-0626","article-title":"Isolation and in vitro propagation of tumorigenic breast cancer cells with stem\/progenitor cell properties","volume":"65","author":"Ponti","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0195","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3892\/or.2014.3330","article-title":"Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines","volume":"32","author":"Jeong","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0200","doi-asserted-by":"crossref","first-page":"17635","DOI":"10.1074\/jbc.M800109200","article-title":"Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells","volume":"283","author":"Bourguignon","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2020.105698_bib0205","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.onc.1206130","article-title":"Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer","volume":"22","author":"Tsai","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jsbmb.2020.105698_bib0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12307-008-0017-0","article-title":"Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts","volume":"2","author":"Sadlonova","year":"2009","journal-title":"Cancer Microenviron."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096007601930740X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096007601930740X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:05:14Z","timestamp":1760745914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096007601930740X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":42,"alternative-id":["S096007601930740X"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105698","relation":{},"ISSN":["0960-0760"],"issn-type":[{"type":"print","value":"0960-0760"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heregulin controls ER\u03b1 and HER2 signaling in mammospheres of ER\u03b1-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105698"}}